甲状腺包膜下ACR TI-RADS 5结节主动监测的可行性与安全性
本研究回顾性纳入675例患者共763个ACR TI-RADS 5级甲状腺结节,按结节距甲状腺包膜距离分为包膜下组(≤2 mm)与非包膜下组(>2 mm),中位随访55个月。结果显示包膜下组与非包膜下组的结节增大、体积增加、新发可疑病灶及淋巴结转移发生率均无显著差异,无远处转移发生。结论为包膜下位置不增加主动监测期间的疾病进展风险。
要点
- ACR TI-RADS 5级包膜下结节主动监测的进展风险与非包膜下结节相当
- 包膜下组患者更年轻且多灶性病变比例更高,需注意全腺体扫查
- 规范随访下主动监测可作为贴近包膜的高度可疑恶性结节的可行管理策略
核心结论
- 包膜下位置与主动监测期间更高的疾病进展风险无关
- 经适当选择和定期随访,主动监测对贴近甲状腺包膜的ACR TI-RADS 5级结节是安全的管理选择
研究设计与样本
- 回顾性研究,2015年至2024年在瑞金医院纳入675例患者共763个ACR TI-RADS 5级结节接受主动监测
- 中位随访时间为55个月
- 疾病进展定义为最大径增加至少3 mm、体积增加至少50%、出现新的可疑甲状腺病灶或淋巴结转移
关键影像表现/征象
- 包膜下组与非包膜下组的结节增大率分别为2.9%与2.7%
- 包膜下组与非包膜下组的体积增加率分别为25.7%与24.5%
- 包膜下组与非包膜下组的新发可疑病灶发生率分别为5.1%与2.4%
- 包膜下组与非包膜下组的淋巴结转移发生率分别为2.3%与2.0%
- 两组均无远处转移发生
诊断标准与关键数值
- 包膜下定义为结节距甲状腺包膜≤2 mm,非包膜下定义为>2 mm
- 疾病进展定义为最大径增加≥3 mm、体积增加≥50%、出现新的可疑甲状腺病灶或淋巴结转移
- 包膜下组与非包膜下组的无进展生存无显著差异(log-rank p = 0.78)
- 包膜下组患者年龄显著更低(33±11岁 vs 43±12岁,p<0.001)
- 包膜下组多灶性病变比例显著更高(21.6% vs 12.5%,p=0.004)
临床应用与阅片要点
- 对贴近包膜的ACR TI-RADS 5级结节,主动监测时需重点观察结节大小、体积变化及新发病灶
- 包膜下组患者多灶性比例更高且更年轻,随访中应全面扫查甲状腺及颈部淋巴结
- 随访中若出现最大径增加≥3 mm、体积增加≥50%或新发淋巴结转移应视为进展并重新评估管理策略
局限性
- 回顾性单中心研究设计存在选择偏倚的可能
- 主动监测纳入标准由临床医生掌握,可能排除部分高风险包膜下结节
- 中位随访55个月尚不足以评价极长期的疾病进展与生存结局
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The safety of active surveillance (AS) in highly suspicious thyroid nodules classified as ACR TI-RADS 5, particularly those located close to the thyroid capsule, has not been fully established. This study aims to assess the feasibility and safety of AS in patients with subcapsular ACR TI-RADS 5 nodules compared with non-subcapsular nodules.
METHODS: This retrospective study included 675 patients with 763 ACR TI-RADS 5 nodules who underwent AS at Ruijin Hospital between 2015 and 2024. Nodules were categorized according to the distance from the thyroid capsule as subcapsular (≤2 mm) or non-subcapsular (>2 mm). Disease progression was defined as an increase in maximum diameter of at least 3 mm, a volume increase of at least 50%, the appearance of new suspicious thyroid lesions, or lymph node metastasis. Clinical and ultrasound characteristics were compared between groups, and progression-free survival was analyzed using the Kaplan-Meier method.
RESULTS: Among the 763 nodules, 175 (22.9%) were subcapsular. The median follow-up duration was 55 months. Patients with subcapsular nodules were younger (33 ± 11 years vs 43 ± 12 years, p < 0.001) and more frequently had multifocal disease (21.6% vs 12.5%, p = 0.004). No significant differences were observed between the subcapsular and non-subcapsular groups in nodule enlargement (2.9% vs 2.7%), volume increase (25.7% vs 24.5%), new lesion development (5.1% vs 2.4%), or lymph node metastasis (2.3% vs 2.0%). No distant metastasis occurred. Progression-free survival did not differ significantly between groups (log-rank p = 0.78).
CONCLUSIONS: Subcapsular location was not associated with a higher risk of disease progression during AS. With appropriate selection and regular follow-up, AS appears to be a safe management option for ACR TI-RADS 5 nodules, including those near the thyroid capsule.
引用
- Hu, Zhou, Zhang, et al. Feasibility and Safety of Active Surveillance in Subcapsular Thyroid Nodules with High Suspicion for Malignancy. Ultrasound Med Biol. 2026. PMID: 41530020. doi:10.1016/j.ultrasmedbio.2025.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。